TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27775416

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral/mindfulness-based group sleep intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Active control 'study skills' intervention
Number of subjects: 144
Study: 24128286

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA) training using a handheld computer for 4 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Increase in cravings reported on EMA prompts
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Coping styles (distraction and disengagement)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Coping style (acceptance)
Number of subjects: 100
Study: 22491480

Group type: EXPERIMENTAL
Intervention: Interferential therapy (IFT) delivered at high, to‐tolerance intensity and high AMF for 30 minutes
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study: 19852789

Group type: COMPARATOR
Intervention: DMSA (dimercapto succinic acid), 3 days for Phase 1, followed by 6 additional rounds in Phase 2
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: DMSA (dimercapto succinic acid), 3 days for Phase 1
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 17237324

Group type: EXPERIMENTAL
Intervention: Behavioral change communication intervention
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 198
Study: 15728754

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Duloxetine (40 mg/day - 120 mg/day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 90
Study: 11685055

Group type: EXPERIMENTAL
Intervention: Topical autologous serum as a tear substitute
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unpreserved normal saline solution as a placebo
Number of subjects: 12
Study: 9742917

Group type: EXPERIMENTAL
Intervention: Surgery plus early postoperative intraperitoneal chemotherapy (mitomycin C on day 1 and 5-fluorouracil on days 2-5)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Surgery plus early postoperative intraperitoneal chemotherapy
Number of subjects: 248

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 248
Study: 7799589

Group type: EXPERIMENTAL
Intervention: Endolymphatic injection of gentamycin and myelopid
Number of subjects: 0
Study: 3167272

Group type: EXPERIMENTAL
Intervention: Microcomputer-based cognitive rehabilitation
Number of subjects: 3
Study: 31727030

Group type: EXPERIMENTAL
Intervention: Gain-framed leaflet
Number of subjects: 11038

Group type: EXPERIMENTAL
Intervention: Loss-framed leaflet
Number of subjects: 11038

Group type: COMPARATOR
Intervention: Control condition (current national leaflet)
Number of subjects: 11038
Study: 28621489

Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil (5-FU)
Number of subjects: 932

Group type: COMPARATOR
Intervention: Vehicle control cream
Number of subjects: 932
Study: 25164513

Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Health Education Control (HEC)
Number of subjects: 63
Study: 23325582

Group type: EXPERIMENTAL
Intervention: Panitumumab treatment
Number of subjects: 241

Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 241
Study: 21508863

Group type: EXPERIMENTAL
Intervention: Evening dose of hydroxyzine 50 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Morning dose of hydroxyzine 50 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19385022

Group type: EXPERIMENTAL
Intervention: Whey protein (10En%)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Casein protein (10En%)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Soy protein (10En%)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Whey protein (25En%)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Casein protein (25En%)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Soy protein (25En%)
Number of subjects: 25
Study: 18225471

Group type: EXPERIMENTAL
Intervention: Non-pharmacological home-based intervention involving up to 13 visits from an occupational therapist
Number of subjects: 272

Group type: COMPARATOR
Intervention: No-treatment control group with nurse arm and one in-home session following trial completion at 6-months
Number of subjects: 272
Study: 14985185

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) supplementation (0.8 or 1.6 g/kg body mass)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) supplementation during a 6-week period
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) supplementation following a 40 km simulated cycling trial
Number of subjects: 27

Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 27
Study: 11238499

Group type: EXPERIMENTAL
Intervention: MSH/ACTH(4-10)
Number of subjects: 36

Group type: COMPARATOR
Intervention: desacetyl-alphaMSH
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9583444

Group type: EXPERIMENTAL
Intervention: Nicorandil (2 mg bolus iv injection followed by continuous infusion of 2-6 mg/h for 3 hours)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 7666817

Group type: EXPERIMENTAL
Intervention: Sequential combination of estradiol valerate and cyproterone acetate (Climen)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Vitamin D3, 300 IU/day
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Climen + Vitamin D3
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study: 2669435

Group type: EXPERIMENTAL
Intervention: Laser trabeculoplasty
Number of subjects: 39

Group type: COMPARATOR
Intervention: Medication therapy
Number of subjects: 39
Study: 1234508

Group type: EXPERIMENTAL
Intervention: SC‐23992 (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone (125 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31008717

Group type: EXPERIMENTAL
Intervention: Processed microvascular tissue (PMVT)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 3
Study: 29114095

Group type: EXPERIMENTAL
Intervention: Direct mechanical thrombectomy (MT)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Bridging therapy (intravenous thrombolysis plus MT)
Number of subjects: 360
Study: 25975338

Group type: EXPERIMENTAL
Intervention: Animal training (pig model)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Artificial simulator training
Number of subjects: 0
Study: 23922184

Group type: EXPERIMENTAL
Intervention: Combined treatment with non‐ablative fractional laser and optimized intense pulsed light (Group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non‐ablative fractional laser only (Group B)
Number of subjects: 36
Study: 22512098

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Classical approach
Number of subjects: 96
Study: 19258204

Group type: EXPERIMENTAL
Intervention: LAAM
Number of subjects: 53

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 53
Study: 17883994

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic therapy including cardiac resynchronization therapy, left ventricular assist devices, and cardiac rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interventions aimed at treatment of acute HF syndromes
Number of subjects: 0

Group type: COMPARATOR
Intervention: General interventions for HF
Number of subjects: 0
Study: 15248853

Group type: EXPERIMENTAL
Intervention: Anti-IgE treatment
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 15635850

Group type: EXPERIMENTAL
Intervention: Training on a bicycle ergometer three times per week for eight weeks, 30 minutes per session at the level of the anaerobic threshold.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (K)
Number of subjects: 38
Study: 10396235

Group type: EXPERIMENTAL
Intervention: Microimmunofluorescence test (MIF) for IgG, IgM, and IgA antibodies to C pneumoniae
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Time resolved fluoroscopic immunoassay (TRIA) for IgG antibodies to C pneumoniae
Number of subjects: 1020
Study: 2072003

Group type: EXPERIMENTAL
Intervention: H tone setting with a 2 mm vented mould
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard hearing aid settings
Number of subjects: 83
Study: 6338993

Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel alone
Number of subjects: 82

Group type: COMPARATOR
Intervention: 2% lignocaine gel with St Mark's Hospital anal dilator
Number of subjects: 82

Group type: COMPARATOR
Intervention: No operation for anterior or lateral anal fissures
Number of subjects: 82
Study: 30895313

Group type: EXPERIMENTAL
Intervention: Large cage (160 × 160 × 62 cm; LC)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Medium cage (120 × 120 × 62 cm; MC)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Small cage (80 × 70 × 62 cm; SC)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Large cage (LC)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Medium cage (MC)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Small cage (SC)
Number of subjects: 575
Study: 30072400

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/day)
Number of subjects: 9340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study: 27044340

Group type: EXPERIMENTAL
Intervention: Icon-based menu labelling initiative
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no icon-based menu labelling)
Number of subjects: 8
Study: 23714321

Group type: EXPERIMENTAL
Intervention: Web-based questionnaire
Number of subjects: 118

Group type: COMPARATOR
Intervention: Paper-and-pencil questionnaire
Number of subjects: 118
Study: 21392601

Group type: EXPERIMENTAL
Intervention: Local infusion of abciximab after aspiration with a 6F Export Aspiration Catheter
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Local infusion of abciximab and no aspiration
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: No local infusion of abciximab and aspiration with a 6F Export Aspiration Catheter
Number of subjects: 452

Group type: COMPARATOR
Intervention: No local infusion of abciximab and no aspiration
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 452
Study: 19707840

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Prior low-risk drinking status at 12 months
Number of subjects: 63
Study: 17311617

Group type: EXPERIMENTAL
Intervention: Folic acid 1 mg/day for 6 months
Number of subjects: 10
Study: 15522379

Group type: EXPERIMENTAL
Intervention: Sustained decrease of visual field (SDVF) defined as a worsening from baseline by 4 units sustained for 3 consecutive 6-month visits
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Sustained decrease of visual field (SDVF) with a worsening of at least 2 units
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Confirmatory tests after a sustained event
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Mean deviation (MD) worsening
Number of subjects: 565
Study: 11503945

Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide (30 mg orally)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 10073847

Group type: EXPERIMENTAL
Intervention: Open infarct-related artery
Number of subjects: 11228

Group type: COMPARATOR
Intervention: Closed infarct-related artery
Number of subjects: 11228
Study: 8006252

Group type: EXPERIMENTAL
Intervention: Angina-guided medical strategy
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Ischemia-guided medical strategy
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Revascularization strategy
Number of subjects: 618

Group type: COMPARATOR
Intervention: All strategies
Number of subjects: 618
Study: 2734234

Group type: COMPARATOR
Intervention: Abnormal uterine bleeding (when dead controls were used)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Placenta praevia (when live controls were used)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Abruptio placentae (when live controls were used)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Multiple birth (when live controls were used)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Pregnancy interval ≤ 12 months (when live controls were used)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Sexually transmitted disease (when live controls were used)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Eclampsia (when live controls were used)
Number of subjects: 148
Study: 22216509

Group type: EXPERIMENTAL
Intervention: Metoprolol (75-300 mg) in combination with chlorthalidone
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo in combination with chlorthalidone
Number of subjects: 23
Study: 29709447

Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Vaccine (QIV)
Number of subjects: 1980
Study: 27142356

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25787041

Group type: EXPERIMENTAL
Intervention: Remote monitoring and office follow-up
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Remote monitoring without physician office care
Number of subjects: 374

Group type: COMPARATOR
Intervention: Usual clinical care with home BP monitoring (Control)
Number of subjects: 374
Study: 24090047

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Blonanserin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Paliperidone
Number of subjects: 300
Study: 21699786

Group type: EXPERIMENTAL
Intervention: Telaprevir (750 mg every 8 h)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Telaprevir + Peginterferon + Ribavirin (TPR)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Peginterferon + Ribavirin (PR)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Telaprevir
Number of subjects: 49
Study: 17927991

Group type: EXPERIMENTAL
Intervention: Integrated care intervention in somatic wards
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control wards (psycho-geriatric)
Number of subjects: 9
Study: 16503678

Group type: EXPERIMENTAL
Intervention: 6 x 1 repetition with 20‐second rest periods (Singles)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 3 x 2 repetitions with 50 seconds rest (Doubles)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 2 x 3 repetitions with 100 seconds rest (Triples)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All interrepetition rest interventions
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional continuous 6RM total power output
Number of subjects: 26
Study: 14577025

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.5%
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: ropivacaine 1%
Number of subjects: 57

Group type: COMPARATOR
Intervention: 0.9% saline solution (Placebo)
Number of subjects: 57
Study: 11284975

Group type: EXPERIMENTAL
Intervention: Reservoir technique
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Globe technique
Number of subjects: 139
Study: 9356529

Group type: EXPERIMENTAL
Intervention: Green tea (900 mL/d)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Black tea (900 mL/d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (900 mL mineral water/d)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: In vitro experiment with high amounts of green or black tea
Number of subjects: 45
Study: 8487564

Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Retrograde cardioplegia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 2959307

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of ipratropium and salbutamol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (rimiterol)
Number of subjects: 36
Study: 30527100

Group type: EXPERIMENTAL
Intervention: Innovative implementation strategy including a computerized decision support system (DSS) and professional audit and feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal implementation strategy of audit and feedback only
Number of subjects: 0
Study: 26708287

Group type: EXPERIMENTAL
Intervention: Statin therapy (duration <1 year)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Statin therapy (duration 1-5 years)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Statin therapy (duration >5 years)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Presence of metabolic syndrome
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Higher lipoprotein(a)
Number of subjects: 98
Study: 25622681

Group type: EXPERIMENTAL
Intervention: Intranasal lignocaine/phenylephrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25927562

Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 0
Study: 21609555

Group type: EXPERIMENTAL
Intervention: Endoscopic surgery by infraclavicular approach
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 42
Study: 18313688

Group type: EXPERIMENTAL
Intervention: Arm weights
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants (no arm weights)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Second control group (not specified)
Number of subjects: 0
Study: 16481389

Group type: EXPERIMENTAL
Intervention: Topotecan at a starting dose of 1.25 mg.m(‐2) with individual dose adjustment, administered intravenously on days 1‐5, every 21 days, for up to six courses.
Number of subjects: 170
Study: 12900586

Group type: EXPERIMENTAL
Intervention: Standard cuff
Number of subjects: 120

Group type: COMPARATOR
Intervention: Large cuff
Number of subjects: 120
Study: 9491720

Group type: EXPERIMENTAL
Intervention: Vagotomy with pyloroplasty
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy with duodenoplasty
Number of subjects: 230
Study: 8473721

Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: l-fenfluramine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 3906545

Group type: EXPERIMENTAL
Intervention: Standard treatment plus intravenous piperacillin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard antibiotic treatment (flucloxacillin plus tobramycin)
Number of subjects: 18
Study: 29995217

Group type: COMPARATOR
Intervention: HPV self-sampling delivered via US mail (SS + Mail)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: HPV self-sampling delivered in-person by a community health worker (IP + SS)
Number of subjects: 600
Study: 27136416

Group type: EXPERIMENTAL
Intervention: Resting state functional connectivity (RSFC) in adolescents with remitted MDD (rMDD)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 23
Study: 25260436

Group type: EXPERIMENTAL
Intervention: Baseline left atrial global longitudinal strain (LAεtotal) < 23.2%
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Baseline left atrial global longitudinal strain (LAεtotal)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Patients maintained sinus rhythm after catheter ablation
Number of subjects: 256
Study: 23801099

Group type: EXPERIMENTAL
Intervention: Shallow trochlea (depth ≤3 mm)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Abnormal medial-to-lateral facet ratio (<0.4)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Abnormal sulcus angle (>170°)
Number of subjects: 304
Study: 20534223

Group type: EXPERIMENTAL
Intervention: NAC (50 mg/kg) bolus just before renal artery declamping (group N)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: NAC (50 mg/kg) bolus plus fenoldopam (0.1 microg/kg/min) continuous infusion (group NF)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: NAC (50 mg/kg) bolus plus dopamine (3 microg/kg/min) continuous infusion (group ND)
Number of subjects: 140

Group type: COMPARATOR
Intervention: No NAC or other infusion (group C)
Number of subjects: 140
Study: 17637608

Group type: EXPERIMENTAL
Intervention: Chronic cannabis use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug-naive controls
Number of subjects: 0
Study: 16177613

Group type: EXPERIMENTAL
Intervention: Right-hand training (RIGHT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Left-hand training (LEFT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nontraining control (CON)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: RIGHT and LEFT combined
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Trained limb agonist EMG activation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Untrained limb EMG
Number of subjects: 39
Study: 12680882

Group type: EXPERIMENTAL
Intervention: Captopril 3 x 25 mg day-1
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10535657

Group type: EXPERIMENTAL
Intervention: ST+MI (standard treatment plus motivational interviewing)
Number of subjects: 121

Group type: COMPARATOR
Intervention: ST (standard treatment)
Number of subjects: 121
Study: 8735864

Group type: EXPERIMENTAL
Intervention: Thiorphan (1.25 mg/mL, 0.5 mL)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 1799915

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 100 mg orally with food every 12 hours
Number of subjects: 93

Group type: COMPARATOR
Intervention: Penicillin V potassium 250 mg orally on an empty stomach every six hours
Number of subjects: 93
Study: 375847

Group type: EXPERIMENTAL
Intervention: levamisole
Number of subjects: 29
Study: 31694849

Group type: EXPERIMENTAL
Intervention: Text message reminders plus routine care
Number of subjects: 434

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 434